Q4 2024 Strides Pharma Science Ltd Earnings Call Transcript
Key Points
- Strides Pharma Science Ltd (BOM:532531) achieved its best year for both revenues and absolute EBITDA in FY24.
- The company successfully optimized its business, focusing on cost containment and operational leverage.
- Significant product approvals, including Sucralfate for the US market, were secured.
- The US market performance met the higher end of the outlook with $250 million in revenue.
- Strides Pharma Science Ltd (BOM:532531) achieved a debt-to-EBITDA ratio of 2.72x, ahead of the scheduled target.
- The institutional segment faced a muted performance due to low allocation of tenders.
- Growth in the US market was partially offset by a weak flu season.
- The company expects significant growth only in H2 FY25 due to the timing of new product approvals.
- The soft gelatin business is expected to have a soft EBITDA in FY25 due to the timing of new product approvals.
- The company faces challenges in launching new products due to capacity constraints, limiting the speed of market entry.
Ladies and gentlemen, good day, and welcome to Strides Pharma Science Limited Q4 FY24 earnings conference call. (Operator Instructions)
Please note that this conference is being recorded, and I now hand the conference over to Abhishek. Thank you, and over to you, Richard.
Thanks. A very good afternoon, and thank you for joining us today for Strides Earnings Call for the fourth quarter and full year ended financial year 2024. Today, we have with us Arun, Founder, Executive Chairperson; and Badree Managing Director designate to share the highlights of the business and financials for the quarter.
I hope you have gone through our results release and the quarterly investor presentation, which have been uploaded on our website as well as stock exchange website. The transcript for this call will be available in a week's time on the company's website. Please note that today's discussion may be forward-looking in nature and must be viewed in relation to the risk pertaining to our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
